SINGAPORE, Sept. 10, 2025 /PRNewswire/ — Cohesity, a leader in AI-powered data security, today announced the appointment of Greg Statton as Chief Technology Officer for the Asia Pacific and Japan (APJ) region. In this newly created role, Statton will lead technology strategy and innovation initiatives across APJ, supporting Cohesity’s mission to deliver next-generation data protection solutions in the region following the successful integration with Veritas’ enterprise data protection business.

Statton will take on the new role, alongside his existing responsibilities of leading innovation and development of Cohesity’s AI solution – Gaia, globally and will report directly to Sunil Moolchandani.  

Statton’s appointment reflects Cohesity’s increased investment in APJ — and in Japan specifically — as a key growth market and strategic priority region for FY26. Cohesity recognise the growing customer requirements for the efficiency and increased business resilience opportunities that advanced, fully integrated, AI and data security solutions can provide in Japan and across the region. The newly created role of Field CTO for APJ, will enable more customer specific requirements in the APJ markets to be answered with specific R&D and solution innovation in the product roadmap, and support deeper engagement with enterprise and government customers across the region.

“Greg brings a rare combination of technical depth, regional insight, and strategic vision that will be critical as we scale our presence across Asia Pacific and Japan,” said Sunil Moolchandani, Chief Strategy Officer, Cohesity. “As we continue to invest in the region — especially in key markets like Japan — Greg’s leadership will play a pivotal role in helping customers adopt our AI-powered data security solutions and strengthen their cyber resilience.

Statton’s new role extends his 10-year career within Cohesity, having served in a variety of sales engineering leadership and technical innovation roles within the business including VP AI Solutions and Senior Director Data & AI within the office of the CTO.   Prior to Cohesity, Statton spent time working at CITRIX, Nutanix and as Google product development specialist. Throughout his career, Statton has been instrumental in advancing cloud, security, and AI technologies across diverse industries.

“In today’s fast-changing data protection environment, organisations across Asia Pacific and Japan need technology partners who understand their unique challenges and can deliver tailored, innovative solutions,” said Greg Statton, CTO, Asia Pacific and Japan, Cohesity. “I am excited to directly support the Cohesity APJ team at such a pivotal time and look forward to driving the next wave of growth and innovation in the region — particularly in Japan — alongside our talented teams and partners.”

About Cohesity
Cohesity is the leader in AI-powered data security. Over 13,600 enterprise customers, including nearly 70% of the Global 500, rely on Cohesity to strengthen their resilience while providing Gen AI insights into their vast amounts of data. Formed from the combination of Cohesity with Veritas’ enterprise data protection business, the company’s solutions secure and protect data on-premises, in the cloud, and at the edge. Backed by NVIDIA, IBM, HPE, Cisco, AWS, Google Cloud, and others, Cohesity is headquartered in Santa Clara, CA, with offices around the globe. To learn more, follow Cohesity on LinkedIn, X, and Facebook.

MELBOURNE, Australia, Sept. 10, 2025 /PRNewswire/ — ADP^®, a global leader in HR and payroll solutions, has opened its new Australia and New Zealand (ANZ) headquarters in Melbourne, marking a fresh chapter in its 41-year journey in the region. The move underscores ADP’s ongoing commitment to supporting clients with future-ready payroll, HR, and workforce management solutions.

Front row from left to right: Jessica Zhang (Senior Vice President, APAC, ADP), Kylie Baullo (General Manager, ANZ & Japan, ADP), Maria Black (President and Chief Executive Officer, ADP), Virginia Magliulo (Executive Vice President, Employer Services International, ADP)

The new workspace in Cremorne brings together regional and local leadership, client-facing teams, and technology experts under one roof. Here, ADP teams can collaborate more closely, innovate more boldly, and continue to help organisations across ANZ adapt to the rapidly changing world of work.

Purpose-built to promote hybrid collaboration, this vibrant, modern space offers flexible work areas, a rooftop garden, and premium end-of-trip facilities. Reflecting ADP’s brand values, the space prioritises employee well-being, inclusive design and modern technology – creating an inspiring environment where innovation and collaboration thrive.

“This new headquarters reflects our long-term investment in the region and our focus on helping clients unlock business value through technology, compliance expertise, and a people-first approach,” said Kylie Baullo, general manager ANZ & Japan, ADP. “It also strengthens our ability to deliver global solutions with local insight – backed by ADP’s trusted heritage.”

With over four decades of presence in the region, ADP remains a trusted partner for thousands of ANZ organisations seeking reliability, compliance, and transformation in payroll and HCM.

About ADP (NASDAQ: ADP)
ADP has been shaping the world of work with innovation and expertise for more than 75 years. As a global leader in HR and payroll solutions, ADP continuously works to solve business challenges for our clients and their workers, from simple, easy-to-use tools for small businesses to fully integrated platforms for global enterprises — and everything in between. Always Designing for People means we’re focused on just that – people. We use our unmatched AI-driven insights and proven expertise to design innovative solutions that help people achieve greater success at work. More than 1.1 million clients across 140+ countries rely on ADP’s exceptional service to support their people and drive their business forward. HR, Talent, Time Management, Benefits, Compliance, and Payroll. Learn more at ADP.com.

Photo – https://laotiantimes.com/wp-content/uploads/2025/09/adp_ribbon_cutting_ceremony.jpg 
Logo – https://laotiantimes.com/wp-content/uploads/2025/09/adp_logo.jpg 

– Amid the rapid proliferation of AI models, Podonos addresses growing demand for performance evaluation and validation, especially in the voice AI domain

– Provides comprehensive testing of pronunciation, emotion, noise tolerance, and persona alignment for both AI model developers and service providers

– NAVER D2SF continues strategic investments in “AI for AI” tools across the full AI value chain

SEONGNAM, South Korea, Sept. 10, 2025 /PRNewswire/ — NAVER D2SF announced a new investment in Podonos, a North America–based startup specializing in voice AI model evaluation and benchmarking. This pre-seed round, led by U.S.-based Serac Ventures, marks Podonos’s first institutional funding, with NAVER D2SF and KAIST Venture Investment Holdings also participating from Korea.

As the number of AI models continues to surge, the need for robust evaluation and verification tools has become increasingly critical. Voice AI, in particular, is gaining rapid adoption in applications such as speech recognition, synthesis, customer service, and media content—and is emerging as a key interface for AI agents. Given the complexity of human speech, performance criteria now extend beyond pronunciation accuracy to include tone, emotion, noise resilience, persona consistency, and user preferences, increasing the demand for tailored model evaluation.

Podonos offers a unique solution by combining a global network of over 150,000 evaluators with its proprietary AI-driven automation engine, delivering voice AI model assessment results within 12 hours. Its platform serves a wide range of clients across the AI value chain, enabling AI model developers to verify, benchmark, and improve their models’ performance, while allowing service providers that leverage AI technologies to identify and monitor models that best align with their specific goals, target audiences, and operational environments.

The company’s evaluation platform is already trusted by notable voice AI startups including Resemble AI, Play AI, and Sanas AI, and has been cited by major tech media and developer communities. Podonos plans to further expand into high-demand sectors such as healthcare, finance, gaming, and advertising, while broadening its capabilities to include multimodal model evaluation.

Yang Sang-hwan, Leader of NAVER D2SF, stated, “As we enter a phase of AI abundance, the importance of ‘AI for AI’—tools that make AI more usable and reliable—is growing. Podonos is one of the few teams globally capable of quantifying and validating the performance of voice AI models. We believe they will play a key role in shaping the global voice AI landscape, with strong potential for synergy with NAVER’s own initiatives.”

Soo-hyun Bae, CEO of Podonos, added, “With this funding, we plan to accelerate hiring and enhance our automated model analysis tools. We look forward to collaborating with NAVER D2SF to deliver higher-quality voice services and grow together.”

NAVER D2SF has consistently invested in “AI for AI” technologies, including startups like Crowdworks, which focuses on AI training data generation, and Nota, which optimizes AI models for edge environments. NAVER D2SF plans to continue making strategic investments across the entire AI development value chain. 

About NAVER

Founded in 1999, NAVER is Korea’s largest Internet company and one of the world’s top tech companies. Leading cutting-edge technologies, NAVER operates No.1 search engine in Korea and holds various business portfolios encompassing commerce, fintech, cloud, AI and robotics, as well as other global online services such as LINE mobile messenger, Webtoon and Webnovel publishing, SNOW video camera app and ZEPETO metaverse platform.

NAVER recorded sales of KRW 10.74 trillion (USD 7.5 billion) in 2024. The company invests approximately 25% of its annual sales on R&D projects, pursuing innovation through continuous research and development of future technologies, such as in robotics, autonomous driving, digital twins, AI, and AR. TEAM NAVER strengthens business portfolios and expands its service regions, including Japan, North America, and Europe.

To learn more, visit www.navercorp.com/en 

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) to include prostate cancer diagnosis.

BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study^[1]) is the first registration-enabling study to evaluate whether the combination of MRI^[2] and PSMA-PET^[3] imaging can improve sensitivity, specificity, and positive and negative predictive values in diagnosing prostate cancer. The aim of the study is to demonstrate that some patients can be effectively stratified to either avoid a biopsy altogether or undergo a single PSMA-PET guided biopsy instead. Telix plans to enrol 204 patients in Australia and the United States (U.S.) for the single arm, multicenter, prospective, open label, longitudinal Phase 3 study.

The first BiPASS™ patient was dosed under the supervision of Principal Investigator Professor Tony Costello AM at the Australian Prostate Centre (APC), and imaged by Professor Rodney Hicks AM, at the Melbourne Theranostic Innovation Centre (MTIC). The first patient biopsy was performed by BiPASS™ Investigator and Clinical Director at APC, Mr. Phil Dundee.

Prof. Costello, Founder and Director, APC said, “Urologists are often faced with the dilemma of whether or not to biopsy. This invasive and often painful procedure carries risks, with many men refusing it altogether. From a clinical perspective, when the biopsy shows low to intermediate risk cancer, it’s unclear whether this represents the true burden of disease or sampling error. Combining MRI and PSMA-PET imaging has the potential to improve both the patient experience and diagnostic accuracy. As such, being part of this study is very important to the APC and our patients.”

Prof. Hicks, Founder, Chair and Chief Medical Officer, MTIC added, “PSMA-PET plus MRI has the potential to fundamentally change prostate cancer diagnosis. Using existing technologies with proven performance in lesion detection at the start of the patient journey could improve the way we stratify patients – safely de-escalating treatment or using a single precision biopsy for diagnosis.”

In the current diagnosis pathway, men with elevated PSA^[4] values can be recommended for MRIs which are often inconclusive. A prostate template biopsy, which typically involves 12 – 20 needle biopsies, is commonly the next step, even in patients deemed as low risk on MRI. However, this non-specific procedure can still miss significant prostate cancer, and can be painful and subject to complications, with many found to be unnecessary. While more than 1 million biopsies are performed in the U.S. each year, up to 75% are negative^[5]. Moreover, one in four patients refuse a recommended biopsy^[6].

Adding an indication for prostate cancer diagnosis has the potential to significantly expand the U.S. market for Telix’s twin commercial PSMA-PET imaging agents by approximately 800,000 scans^[7].

BiPASS™ builds on a promising body of research, including the PRIMARY^[8]. and PRIMARY2^[9] studies, which demonstrated the advantages of MRI + PSMA-PET imaging in defining or ruling out prostate cancer, or in recommending participants undergo active surveillance before an invasive biopsy is performed. Professor Louise Emmett, Principal Investigator for PRIMARY, will continue her pioneering work as a BiPASS™ Steering Committee member and an Investigator on the study.  

Prof. Emmett, Director of Theranostics and Nuclear Medicine, St Vincent’s Hospital, said, “My colleagues and I have built a significant body of research on the benefits of PSMA-PET and MRI, documented in the PRIMARY studies and we are pleased to see Telix expand on this research with this registration-enabling study. BiPASS™ has the potential to positively impact all men by changing clinical practice and guidelines to facilitate earlier, more accurate prostate cancer diagnosis.” 

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Gozellix® (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the U.S. FDA^[10].

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.)  

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com 

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices 

Cautionary Statement Regarding Forward-Looking Statements  

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.  

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.  

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.  

Trademarks and Trade Names

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.  

©2025 Telix Pharmaceuticals Limited. All rights reserved. 

AUCKLAND, New Zealand, Sept. 10, 2025 /PRNewswire/ — Allianz Partners, a global leader in insurance and assistance services, is pleased to announce the appointment of Okan Özdemir as its new Chief Officer for Health and Board Member, effective September 1, 2025. In this role, Okan will report directly to Allianz Partners CEO Tomas Kunzmann. 

Okan Özdemir joins Allianz Partners from Allianz Türkiye, where he served as Chief Health Officer and Executive Board Member since 2019. With over 24 years of strong leadership at Allianz in a number of strategic roles including Chief Marketing Officer, he has been instrumental in advancing the company’s market leadership and growth in health insurance while overseeing a significant digital transformation within the business. 

Okan holds a degree in Business Administration from Istanbul University and a Master’s degree in Business from the European School of Management and Technology.

In his new global position, Okan will continue to strengthen Allianz Partners’ health line of business and health portfolio worldwide, while expanding its market leadership in the global health segment.

Okan Özdemir will succeed Ida Luka-Lognoné, who has led the Health business since 2015, overseeing significant growth and expansion, including developing new customer segments and expanding global operations. Ida has had a successful career spanning 30 years at Allianz Group, the last ten years of which at Allianz Partners where she played a key role in transforming the Health business into a global leader in innovative health solutions. Her leadership was instrumental in creating a culture of customer-centricity and driving strategic initiatives that positioned Allianz Partners at the forefront of the industry.

Tomas Kunzmann, CEO of Allianz Partners, commented: “We are pleased to welcome Okan as our new Chief Officer for Health, following Ida Luka-Lognoné who has made a lasting impact on our organization. Okan’s deep know-how in Health as well as his experience in digital transformation will serve well in the further expansion of the Health business and it reflects Allianz Partners’ strong momentum and our ambition to double revenues by 2030. Health remains a critical pillar of our growth strategy, and I am confident that under his leadership, we will continue to introduce innovative solutions that deliver value and peace of mind to millions of customers worldwide.” 

Kevin Blyth, MD of Allianz Partners NZ, commented: “I’m excited for Okan’s new global leadership role. While health isn’t yet part of our local market in New Zealand, his expertise will strengthen Allianz Partners’ global offerings. Ida’s support and expertise, particularly with our New Zealand student business, was invaluable. Strong leadership at the Group level ensures our customers and partners here continue to benefit from Allianz’s renowned innovation and focus”.

About Allianz Partners   

Allianz Partners is a world leader in B2B2C insurance and assistance, offering global solutions that span travel insurance, mobility, assistance, health insurance and employee benefits. Customer driven, our innovative experts are redefining insurance services by delivering future-ready, high-tech high-touch products and solutions that go beyond traditional insurance. Our products are embedded seamlessly into our partners’ businesses, sold through intermediary channels or directly to customers through the Allianz brand. Present in over 73 countries, our 22,600 employees speak 70 languages, handle over 95 million cases each year, and are motivated to go the extra mile to offer peace of mind to our customers around the world.    

For more information, please visit: www.allianz-partners.com  

About Allianz Partners New Zealand

Based in Auckland, specialising locally in providing and managing assistance services, travel insurance, student insurance and pet insurance through our New Zealand and international business partners. Our strength lies in combining the solidarity and trust that comes with being part of an established global organisation with the local expertise of our New Zealand team.

For more local information, please visit: http://www.allianzpartners.co.nz

Social media 

Follow us on X @AllianzPartners  

Follow us on LinkedIn Allianz Partners  

Follow us on LinkedIn Allianz Partners New Zealand

Follow us on YouTube /allianzpartners  

Follow us on Instagram @allianzpartners